NCT03769194View on ClinicalTrials.gov

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

PHASE2CompletedINTERVENTIONAL
Enrollment

572

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

December 18, 2019

Study Completion Date

October 2, 2020

Conditions
Lyme Borreliosis
Interventions
BIOLOGICAL

VLA15

a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate

BIOLOGICAL

Placebo

Placebo: PBS (Phosphate Buffered Saline)

Trial Locations (9)

9000

Cevac Center for vaccinology, Ghent

10117

Berliner Centrum für Reise- und Tropenmedizin (BCRT), Berlin

13706

Regional Clinical Research, Inc., Endwell

13901

United Medical Associates, Binghamton

14609

Rochester Clinical Research Inc., Rochester

20359

Universitätsklinikum Hamburg-Eppendorf, Hamburg

06460

Clinical Research Consulting, LLC, Milford

06905

Stamford Therapeutics Consortium, Stamford

02886

Omega Medical Research, Warwick

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03769194 - Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. | Biotech Hunter | Biotech Hunter